连花清瘟颗粒治疗新型冠状病毒肺炎的疗效与安全性：系统评价与Meta分析方案
Efficacy and safety of Lian-Hua Qing-Wen granule for COVID-2019: A protocol for systematic review and meta-analysis.
作者信息
Hu Zhipeng, Yang Maoyi, Xie Chunguang
机构信息
Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan Province, PR China.
出版信息
Medicine (Baltimore). 2020 Jun 5;99(23):e20203. doi: 10.1097/MD.0000000000020203.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a global pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Since the outbreak, the disease has caused more than 60,502 deaths worldwide. Lian-Hua Qing-Wen Granule (LHQWG) is widely used in treating COVID-19 in China. However, there is no evidence that LHQWG is effective for COVID-19.
METHODS AND ANALYSIS
A comprehensive literature search will be conducted. Two methodological trained researchers will read the title, abstract and full texts and independently select the qualified literature according to inclusion and exclusion criteria. After assessment of the risk of bias and data extraction, we will conduct meta-analyses for outcomes related to COVID-19. The heterogeneity of data will be investigated by Cochrane X and I tests. Publication bias assessment will be conducted by funnel plot analysis and Egger test.
RESULTS
The results of our research will be published in a peer-reviewed journal.
CONCLUSION
Our study aims to systematically present the clinical evidence of LHQWG in treating COVID-19, which will be of significant meaning for further research and clinical practice.
OSF REGISTRATION NUMBER
10.17605/OSF.IO/27SBU.
背景
2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的全球大流行疾病。自疫情爆发以来，该疾病已在全球造成超过60502人死亡。连花清瘟颗粒在中国被广泛用于治疗COVID-19。然而，尚无证据表明连花清瘟颗粒对COVID-19有效。
方法与分析
将进行全面的文献检索。两名经过方法学培训的研究人员将阅读标题、摘要和全文，并根据纳入和排除标准独立选择合格文献。在评估偏倚风险和进行数据提取后，我们将对与COVID-19相关的结局进行荟萃分析。将通过Cochrane X和I检验研究数据的异质性。将通过漏斗图分析和Egger检验进行发表偏倚评估。
结果
我们的研究结果将发表在同行评审期刊上。
结论
我们的研究旨在系统地展示连花清瘟颗粒治疗COVID-19的临床证据，这对进一步的研究和临床实践具有重要意义。
开放科学框架注册号
10.17605/OSF.IO/27SBU。
Zotero 插件